Literature DB >> 9267005

Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation.

A Vanderplasschen1, M Hollinshead, G L Smith.   

Abstract

Vaccinia virus (VV) produces two antigenically and structurally distinct infectious virions, intracellular mature virus (IMV) and extracellular enveloped virus (EEV). EEV is important for the efficient dissemination of virus both in vivo and in vitro where it causes formation of comet-shaped virus plaques. Here, we show that EEV, in contrast to IMV, is resistant to neutralization by antibodies bound to its surface. However, antibodies against EEV can prevent comet formation in cell culture. To explain this apparent paradox, we investigated the mechanism by which antibodies inhibit comet formation and demonstrated that antibodies prevent EEV release from infected cells, and consequently comet formation, by agglutination of the virus on the cell surface. Two complementary observations allow this conclusion: first, electron microscopy showed that infected cells incubated with medium containing anti-vaccinia virus antibodies have virus aggregates on their surface; second, culture medium from these cells contained a 4 log10 fold reduction in the physical particle/ml titre in comparison with control culture. A mechanism by which antibodies to EEV proteins provide immunological protection is thus restriction of EEV release rather than neutralization of free EEV particles.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9267005     DOI: 10.1099/0022-1317-78-8-2041

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  43 in total

1.  Using confocal microscopy to study virus binding and entry into cells.

Authors:  A Vanderplasschen; G L Smith
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

2.  An intravenous stimulus package for oncolytic virotherapy.

Authors:  Richard Vile; Alan Melcher
Journal:  Mol Ther       Date:  2011-11       Impact factor: 11.454

3.  Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Authors:  Aklile Berhanu; Rebecca L Wilson; Dana L Kirkwood-Watts; David S King; Travis K Warren; Susan A Lund; Lindsay L Brown; Alex K Krupkin; Erin Vandermay; Will Weimers; Kady M Honeychurch; Douglas W Grosenbach; Kevin F Jones; Dennis E Hruby
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

4.  A novel cellular protein, VPEF, facilitates vaccinia virus penetration into HeLa cells through fluid phase endocytosis.

Authors:  Cheng-Yen Huang; Tsai-Yi Lu; Chi-Horng Bair; Yuan-Shau Chang; Jeng-Kuan Jwo; Wen Chang
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

5.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Authors:  Caroline J Breitbach; James Burke; Derek Jonker; Joe Stephenson; Andrew R Haas; Laura Q M Chow; Jorge Nieva; Tae-Ho Hwang; Anne Moon; Richard Patt; Adina Pelusio; Fabrice Le Boeuf; Joe Burns; Laura Evgin; Naomi De Silva; Sara Cvancic; Terri Robertson; Ji-Eun Je; Yeon-Sook Lee; Kelley Parato; Jean-Simon Diallo; Aaron Fenster; Manijeh Daneshmand; John C Bell; David H Kirn
Journal:  Nature       Date:  2011-08-31       Impact factor: 49.962

6.  A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.

Authors:  Pragatheeshwar Thirunavukarasu; Magesh Sathaiah; Michael C Gorry; Mark E O'Malley; Roshni Ravindranathan; Frances Austin; Steven H Thorne; Zong Sheng Guo; David L Bartlett
Journal:  Mol Ther       Date:  2013-02-26       Impact factor: 11.454

7.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

8.  Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination.

Authors:  Garilyn M Jentarra; Michael C Heck; Jin Won Youn; Karen Kibler; Jeffrey O Langland; Carole R Baskin; Olga Ananieva; Yung Chang; Bertram L Jacobs
Journal:  Vaccine       Date:  2008-04-08       Impact factor: 3.641

9.  Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Authors:  Padma Sampath; Jun Li; Weizhou Hou; Hannah Chen; David L Bartlett; Steve H Thorne
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

10.  Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane.

Authors:  Jing Jin; Jesús G Galaz-Montoya; Michael B Sherman; Stella Y Sun; Cynthia S Goldsmith; Eileen T O'Toole; Larry Ackerman; Lars-Anders Carlson; Scott C Weaver; Wah Chiu; Graham Simmons
Journal:  Cell Host Microbe       Date:  2018-08-23       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.